BioMarin shares spike ahead of cancer drug review at ASCO; Biogen Idec names Artavanis-Tsakonas as CSO; Spinoff biotech nabs $15M;

 @FierceBiotech: Feature: Top 10 Biotech CEO Pay Packages of 2012. Special Report | Follow @FierceBiotech

 @JohnCFierce: A "rational" market finally develops an appetite for biotech IPOs. Story | Follow @JohnCFierce

 @RyanMFierce: Cash-strapped biotech Seaside Tx fails PhIII test for pioneering Fragile X drug. More | Follow @RyanMFierce

> BioMarin ($BMRN) shares surged yesterday as analysts whetted investors' appetite for its upcoming review of its PARP inhibitor BMN-673 at ASCO. Story

> Biogen Idec ($BIIB) formally named Spyros Artavanis-Tsakonas as the company's chief scientific officer. Dr. Artavanis-Tsakonas had served as interim CSO while on sabbatical from Harvard Medical School. Release

> Shares of Oncolytics Biotech ($ONCY) jumped on positive preliminary data for its mid-stage melanoma trial of Reolysin. Story

> Burlingame, CA-based Apexigen, a spinoff of Epitomics, has raised $15 million, according to a filing with the SEC. MedCity News reports that the biotech is using monoclonal antibody tech to discover new cancer drugs. Story

> Celgene ($CELG) says the FDA is approving priority review status for its sNDA on Abraxane for pancreatic cancer. Release

Medical Device News

 @FierceMedDev: Stryker, OrthoSensor renew knee replacement co-marketing agreement. More | Follow @FierceMedDev

 @MarkHFierce: 2013 nominations for the FMD Fierce 15 have begun. More | Follow @MarkHFierce

 @DamianFierce: The year is young, but med tech companies are already slashing thousands of jobs. Here's a look at the deepest cuts. Report | Follow @DamianFierce

> Eli Lilly, Corgenix ink cancer drug companion Dx deal. Article

> Boston Scientific's strong results fuel hope for renal denervation success. Story

Pharma News

 @FiercePharma: Forest Labs' Howard Solomon to retire from CEO job after 37 years up top, the last few rather stormy. More | Follow @FiercePharma

 @EricPFierce: GlaxoSmithKline says Aussie strong dollar, wages lead to 120 job cuts at packing plant in Australia. Article | Follow @EricPFierce

> Merck, Lilly, Pfizer share top billing in $1B doc-payments list. Story

> Forest Labs CEO to step aside at year's end after decades at the helm. News

> Daiichi accuses Ranbaxy shareholders of hiding info before buyout. Article

Pharma Manufacturing News

> J&J consumer healthcare faces more issues, this time in Brazil. Item

> Glaxo packs up a tablet packaging line in Australia. More

> FDA cites Boehringer Ingelheim plant in Germany. Article

> Malaysia's Pharmaniaga slates drug plant in Saudi Arabia. Story

Vaccines News

> Sanofi edges closer to universal flu vaccine. More

> Pfizer points to pandemic potential of Prevnar 13. Item

> Inertia at Pakistan's NIH threatening vaccine programs. Article

> Old whooping cough vax linked with better protection. Story

> Analyst taps Bristol, Roche cancer immunotherapies for explosive growth. News

And Finally… A lethal, SARS-like coronavirus has killed another person in Saudi Arabia, bringing the death toll to 17. Story


Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.